U.S. Markets closed

Surging Earnings Estimates Signal Good News for Xenoport (XNPT)

Zacks Equity Research

Xenoport, Inc. XNPT is a biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on XNPT’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Xenoport could be a solid choice for investors.

Current Quarter Estimates for XNPT

In the past 30 days, 1 estimate has gone higher for Xenoport, with no downward revisions in the same time period. The trend has been pretty favorable too, with estimates increasing from a loss of 24 cents a share 30 days ago, to a loss of 22 cents a share today, a move of 9.1%.

Current Year Estimates for XNPT

Meanwhile, Xenoport’s current year figures are also looking quite promising, with 1 estimate moving higher in the past month, and 1 going lower. The consensus estimate trend has seen a boost for this time frame, increasing from a loss of 80 cents per share 30 days ago to a loss of 68 cents per share today, an increase of 17.6%.

Bottom Line

The stock has also started to move higher lately, adding 71.6% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
XENOPORT INC (XNPT): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research